Ingen internetforbindelse — viser den gemte version af siden.

Sanofi ADR

USUSD
← Til screeneren

Sanofi ADR (VI:SANO) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om virksomheden

Websted
sanofi.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
PARIS, France
Administrerende direktør
Paul Hudson
Ansatte
106 566
Grundlagt
2004
Børsnoteret siden
04.10.2017 (VI:SANO)
Udestående aktier
1.22 mia. pr. 2025-12-31
Free float
2.16 mia.
Markedsværdi
98.67 mia. USD
Insidere
0%
Institutionelle investorer
8.02%
Branche (SIC)
Pharmaceutical Preparations
Juridisk form
QVPB
ISIN
FR0000120578
LEI
549300E9PC51EN656011
Udbetalingsgrad
0%
FCF
10.8 mia. EUR
Gæld
18.7 mia. EUR
1.0 år FCF
Udbyttestreak
23 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.12.2025 (selskabets seneste rapport).
Beskrivelse

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Børser og tickere

BørsTickerValutaPrisType
US USA StocksSNYNF OTCUSD78.99 -1.19%almindelige aktier
LSE London Stock Exchange0O59 IOBEUR71.63 +0.72%almindelige aktier
MI Borsa Italiana (Milan)1SAN sekundærEUR71.64 +0.90%almindelige aktier
PA Euronext ParisSAN primærEUR71.52 +0.83%almindelige aktier
VI Vienna Stock ExchangeSANO sekundærEUR71.3 +1.03%almindelige aktier
XETRA XetraSNW sekundærEUR71.78 -1.21%almindelige aktier

Kurs over 3 måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

De sidste 12 måneder, VI:SANO: 4.12 EUR (1 udb.)

Sanofi ADR (SANO) udbetaler udbytte én gang om året. I løbet af de sidste 12 måneder blev der betalt 4.12 EUR pr. Aktie (betalinger: 1). Det svarer til cirka 5.78% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 04.05.2027. Uafbrudt udbyttehistorik: 23 år.

Ex-datoUdbetalingBeløb%TypeTicker
2026-05-052026-05-074.1200 EUR5.8/5.8 %årligVI:SANO
2025-05-122025-05-143.9200 EUR5.5/5.5 %årligVI:SANO
2024-05-13—3.7600 EUR5.3/10.3 %årligVI:SANO
2023-05-30—3.5600 EUR5.0/5.0 %årligVI:SANO
2022-05-06—3.3300 EUR4.7/4.7 %årligVI:SANO

Nyheder denne uge

Endnu ingen nyheder fra virksomhedens websted.

annonce

Største ejere

EjerAndelAktierRapportdato
Dodge & Cox Inc.10.54%28.09 mio.2026-06-30
Dodge & Cox Funds-Dodge…7.84%20.9 mio.2026-06-30
Morgan Stanley4.02%10.7 mio.2026-06-30
Fisher Asset Management,…3.99%10.63 mio.2026-06-30
Bank of America Corporat…3%8.01 mio.2026-06-30
Invesco Ltd.2.55%6.8 mio.2026-06-30
JPMORGAN CHASE & CO2.47%6.57 mio.2026-06-30
Mondrian Investment Part…2.07%5.52 mio.2026-06-30
Brandes Investment Partn…1.55%4.14 mio.2026-06-30
AIM Sector Funds (Invesc…1.51%4.03 mio.2026-04-30
Federated Hermes, Inc.1.44%3.85 mio.2026-06-30
Boston Partners1.44%3.84 mio.2026-06-30
VANGUARD STAR FUNDS-Vang…1.31%15.85 mio.2026-07-31
Putnam ETF Trust-Putnam…1.26%3.36 mio.2026-05-31
VANGUARD TAX-MANAGED FUN…0.87%10.53 mio.2026-06-30
iShares Trust-iShares Co…0.67%8.11 mio.2026-08-31
Dodge & Cox Funds-Dodge…0.63%1.67 mio.2026-06-30
AMERICAN MUTUAL FUND0.59%1.58 mio.2026-06-30
American Century Capital…0.37%976 5612026-06-30
Bridge Builder Trust-Bri…0.36%967 1002026-06-30
Fidelity Concord Street…0.35%4.24 mio.2026-07-31
VanEck ETF Trust-VanEck…0.35%938 5612026-08-31
Dodge & Cox Funds-Dodge…0.33%4.04 mio.2026-06-30
iShares Trust-iShares MS…0.32%3.89 mio.2026-08-31
Capital World Growth & I…0.3%3.67 mio.2026-06-30
-Victory Pioneer Core Eq…0.3%799 4872026-06-30
Fidelity Covington Trust…0.3%797 1842026-08-31
NEW PERSPECTIVE FUND0.29%3.56 mio.2026-06-30
Federated Hermes Eqy. Fd…0.29%3.48 mio.2026-07-31
Bridge Builder Trust-Bri…0.29%3.44 mio.2026-06-30
Pacer Advisors, Inc.0.1%1.16 mio.2026-06-30
Generali Investments Cee…0%29 3392026-06-30
Paradigm Asset Managemen…0%19 2002026-06-30
Gamma Investing LLC0%582026-06-30
L'Oréal———